Open Government Portal
Opioid products need to include specific content within their RMP to address: the risk and uncertainties of opioid-related harms in …
The RMP summary should include specific sections, which mirror the EU RMP Summary format sections.
A Canadian-specific addendum should address: risks or uncertainties that are unique to the Canadian context, and measures that the manufacturer …
Each year, Health Canada receives thousands of reports of suspected adverse reactions (side effects) about drugs and natural health products …
To ensure that advertising material meets Canadian regulatory standards for advertisements for drugs and medical devices, advertising preclearance agencies (APAs) …
The following is a list of health product advisories, type I drug recalls and summaries of completed safety reviews published …
The following is a list of health product advisories, type I drug recalls and summaries of completed safety reviews published …
The following is a list of health product advisories, type I drug recalls and summaries of completed safety reviews published …
The following is a list of health product advisories, type I drug recalls and summaries of completed safety reviews published …
The following is a list of health product advisories, type I drug recalls and summaries of completed safety reviews published …